Andhra Pradesh Minister for Industries and Information Technology Nara Lokesh inaugurated a ₹2,300 crore greenfield pharmaceutical manufacturing facility by Blue Jet Healthcare Limited in the state. The ultra-modern plant will focus on producing high-value active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms, significantly boosting Andhra Pradesh’s position as a global pharma hub while creating thousands of skilled jobs and contributing to India’s self-reliance in critical drug manufacturing.
Glimpse:
The new Blue Jet Healthcare facility, spread across a large industrial plot in Andhra Pradesh, features state-of-the-art GMP-compliant production blocks, advanced R&D labs, quality control centres, and dedicated capacity for oncology, cardiovascular, anti-diabetic, and anti-infective APIs and formulations. The ₹2,300 crore investment includes backward integration for key starting materials, zero-liquid discharge systems, and export-oriented infrastructure to serve regulated markets (US, Europe). The plant is expected to commence commercial production in phases starting late 2026 and generate over 2,500 direct jobs upon full capacity.
Andhra Pradesh Minister for Industries and Information Technology Nara Lokesh formally inaugurated Blue Jet Healthcare Limited’s ₹2,300 crore greenfield pharmaceutical manufacturing facility in the state on February 27, 2026. The event was attended by senior government officials, industry leaders, and Blue Jet executives, marking a major milestone in the state’s aggressive push to attract large-scale investments in the pharmaceutical and life sciences sector under its investor-friendly policies.
The new plant represents one of the largest single investments in Andhra Pradesh’s pharma ecosystem in recent years. Spread across a strategically located industrial site with excellent connectivity, the facility includes multiple dedicated production blocks for high-potency APIs, advanced intermediates, and finished dosage forms, with a strong focus on complex molecules in oncology, cardiovascular, anti-diabetic, anti-infective, and CNS therapeutic areas. Blue Jet has incorporated cutting-edge technologies such as continuous manufacturing, automated synthesis, and zero-liquid discharge effluent treatment systems to meet stringent environmental and quality standards required for regulated markets like the US, Europe, and Japan.
Blue Jet Healthcare Chairman and Managing Director Shyam Chimakurthi stated that the facility will significantly enhance the company’s backward integration capabilities by producing critical starting materials and key intermediates in-house, reducing dependency on imports and improving supply chain resilience. The plant is designed with scalability in mind, with initial commercial production scheduled to begin in late 2026 and full ramp-up targeted by 2028–29. Upon completion, it is expected to generate over 2,500 direct jobs and thousands more indirectly through ancillary services, logistics, and vendor ecosystems.
Minister Nara Lokesh highlighted that the project aligns perfectly with Andhra Pradesh’s vision of becoming a global pharma and life sciences hub. He noted the state’s advantages including plug-and-play industrial parks, single-window clearances via the Nivesh Mitra portal, power subsidies, stamp duty exemptions, and export facilitation which have already attracted multiple large pharma investments in recent years. The minister assured Blue Jet of full government support for expedited regulatory approvals, infrastructure linkages, and skill development programs to train local talent for high-tech manufacturing roles.
The launch underscores the growing momentum in India’s pharmaceutical sector, particularly in states like Andhra Pradesh, Telangana, and Gujarat, where policy incentives, talent availability, and manufacturing ecosystem maturity are driving large-scale greenfield projects. Blue Jet’s investment is expected to contribute to India’s goal of increasing pharma exports and reducing reliance on imported APIs, while strengthening the domestic supply chain for critical medicines.
“Andhra Pradesh is open for business and we are committed to making it the preferred destination for world-class pharmaceutical manufacturing. Projects like Blue Jet’s ₹2,300 crore facility will create jobs, boost exports, and strengthen India’s position in global healthcare.”
By
HB Team
